Literature DB >> 23917093

Pathology of multiple sclerosis: where do we stand?

Bogdan F Gh Popescu1, Istvan Pirko, Claudia F Lucchinetti.   

Abstract

PURPOSE OF REVIEW: This article summarizes the pathologic features of multiple sclerosis (MS) and other inflammatory demyelinating diseases and discusses neuropathologic studies that have yielded novel insights into potential mechanisms of demyelination. RECENT
FINDINGS: The pathologic hallmark of MS consists of focal demyelinated plaques within the CNS, with variable degrees of inflammation, gliosis, and neurodegeneration. Active MS lesions show a profound pathologic heterogeneity with four major patterns of immunopathology, suggesting that the targets of injury and mechanisms of demyelination in MS may be different in different disease subgroups. Recent pathologic studies have suggested that the subarachnoid space and cortex may be initial sites and targets of the MS disease process, that inflammatory cortical demyelination is present early in MS, and that meningeal inflammation may drive cortical and white matter injury in some MS patients.
SUMMARY: MS is heterogeneous with respect to clinical, genetic, radiographic, and pathologic features; surrogate MRI, clinical, genetic, serologic, and/or CSF markers for each of the four immunopatterns need to be developed in order to recognize them in the general nonbiopsied MS population. Inflammatory cortical demyelination is an important early event in the pathogenesis of MS and may be driven by meningeal inflammation. These observations stress the importance of developing imaging techniques able to capture early inflammatory cortical demyelination in order to better understand the disease pathogenesis and to determine the impact of potential disease-modifying therapies on the cortex.

Entities:  

Mesh:

Year:  2013        PMID: 23917093      PMCID: PMC3915566          DOI: 10.1212/01.CON.0000433291.23091.65

Source DB:  PubMed          Journal:  Continuum (Minneap Minn)        ISSN: 1080-2371


  63 in total

Review 1.  Association between pathological and MRI findings in multiple sclerosis.

Authors:  Massimo Filippi; Maria A Rocca; Frederik Barkhof; Wolfgang Brück; Jacqueline T Chen; Giancarlo Comi; Gabriele DeLuca; Nicola De Stefano; Bradley J Erickson; Nikos Evangelou; Franz Fazekas; Jeroen J G Geurts; Claudia Lucchinetti; David H Miller; Daniel Pelletier; Bogdan F Gh Popescu; Hans Lassmann
Journal:  Lancet Neurol       Date:  2012-03-19       Impact factor: 44.182

Review 2.  Pathology of demyelinating diseases.

Authors:  Bogdan F Gh Popescu; Claudia F Lucchinetti
Journal:  Annu Rev Pathol       Date:  2012       Impact factor: 23.472

3.  A case of multiple sclerosis presenting with inflammatory cortical demyelination.

Authors:  B F Gh Popescu; R F Bunyan; J E Parisi; R M Ransohoff; C F Lucchinetti
Journal:  Neurology       Date:  2011-05-17       Impact factor: 9.910

4.  Postmortem verification of MS cortical lesion detection with 3D DIR.

Authors:  A Seewann; E-J Kooi; S D Roosendaal; P J W Pouwels; M P Wattjes; P van der Valk; F Barkhof; C H Polman; J J G Geurts
Journal:  Neurology       Date:  2012-01-04       Impact factor: 9.910

5.  Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes.

Authors:  Shannon R Hinson; Michael F Romero; Bogdan F Gh Popescu; Claudia F Lucchinetti; James P Fryer; Hartwig Wolburg; Petra Fallier-Becker; Susan Noell; Vanda A Lennon
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-29       Impact factor: 11.205

6.  No MRI evidence of cortical lesions in neuromyelitis optica.

Authors:  Massimiliano Calabrese; Mi Sun Oh; Alice Favaretto; Francesca Rinaldi; Valentina Poretto; Sara Alessio; Byung-Chul Lee; Kyung-Ho Yu; Hyeo-Il Ma; Paola Perini; Paolo Gallo
Journal:  Neurology       Date:  2012-09-19       Impact factor: 9.910

7.  Inflammatory cortical demyelination in early multiple sclerosis.

Authors:  Claudia F Lucchinetti; Bogdan F G Popescu; Reem F Bunyan; Natalia M Moll; Shanu F Roemer; Hans Lassmann; Wolfgang Brück; Joseph E Parisi; Bernd W Scheithauer; Caterina Giannini; Stephen D Weigand; Jay Mandrekar; Richard M Ransohoff
Journal:  N Engl J Med       Date:  2011-12-08       Impact factor: 91.245

8.  Potassium channel KIR4.1 as an immune target in multiple sclerosis.

Authors:  Rajneesh Srivastava; Muhammad Aslam; Sudhakar Reddy Kalluri; Lucas Schirmer; Dorothea Buck; Björn Tackenberg; Veit Rothhammer; Andrew Chan; Ralf Gold; Achim Berthele; Jeffrey L Bennett; Thomas Korn; Bernhard Hemmer
Journal:  N Engl J Med       Date:  2012-07-12       Impact factor: 91.245

9.  NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury.

Authors:  Marie T Fischer; Rakhi Sharma; Jamie L Lim; Lukas Haider; Josa M Frischer; Joost Drexhage; Don Mahad; Monika Bradl; Jack van Horssen; Hans Lassmann
Journal:  Brain       Date:  2012-03       Impact factor: 13.501

Review 10.  Meningeal and cortical grey matter pathology in multiple sclerosis.

Authors:  Bogdan F Gh Popescu; Claudia F Lucchinetti
Journal:  BMC Neurol       Date:  2012-03-07       Impact factor: 2.474

View more
  87 in total

1.  White and gray matter damage in primary progressive MS: The chicken or the egg?

Authors:  Benedetta Bodini; Declan Chard; Daniel R Altmann; Daniel Tozer; David H Miller; Alan J Thompson; Claudia Wheeler-Kingshott; Olga Ciccarelli
Journal:  Neurology       Date:  2015-12-16       Impact factor: 9.910

2.  Diffusion tensor imaging identifies aspects of therapeutic estrogen receptor β ligand-induced remyelination in a mouse model of multiple sclerosis.

Authors:  Kelley C Atkinson; Jeong Bin Lee; Jonathan P C Hasselmann; Sung Hoon Kim; Alyson Drew; Joselyn Soto; John A Katzenellenbogen; Neil G Harris; Andre Obenaus; Seema K Tiwari-Woodruff
Journal:  Neurobiol Dis       Date:  2019-06-18       Impact factor: 5.996

3.  Differences in the Reponses to Apheresis Therapy of Patients With 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis.

Authors:  Lidia Stork; David Ellenberger; Tim Beißbarth; Tim Friede; Claudia F Lucchinetti; Wolfgang Brück; Imke Metz
Journal:  JAMA Neurol       Date:  2018-04-01       Impact factor: 18.302

4.  MiR-125a-5p Regulates Vitamin D Receptor Expression in a Mouse Model of Experimental Autoimmune Encephalomyelitis.

Authors:  Han-Chun Long; Rui Wu; Chun-Feng Liu; Fei-Long Xiong; Zu Xu; Dian He; Yi-Fan Zhang; Bing Shao; Ping-An Zhang; Guang-Yin Xu; Lan Chu
Journal:  Neurosci Bull       Date:  2019-08-19       Impact factor: 5.203

Review 5.  Neuromyelitis optica spectrum disorders.

Authors:  Eoin P Flanagan; Brian G Weinshenker
Journal:  Curr Neurol Neurosci Rep       Date:  2014-09       Impact factor: 5.081

6.  Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions.

Authors:  Ulrike W Kaunzner; Yeona Kang; Shun Zhang; Eric Morris; Yihao Yao; Sneha Pandya; Sandra M Hurtado Rua; Calvin Park; Kelly M Gillen; Thanh D Nguyen; Yi Wang; David Pitt; Susan A Gauthier
Journal:  Brain       Date:  2019-01-01       Impact factor: 13.501

7.  pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis.

Authors:  David Kremer; Joel Gruchot; Vivien Weyers; Lisa Oldemeier; Peter Göttle; Luke Healy; Jeong Ho Jang; Yu Kang T Xu; Christina Volsko; Ranjan Dutta; Bruce D Trapp; Hervé Perron; Hans-Peter Hartung; Patrick Küry
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-18       Impact factor: 11.205

8.  Balance in multiple sclerosis: relationship to central brain regions.

Authors:  Richard L Doty; Michael R MacGillivray; Hussam Talab; Isabelle Tourbier; Megan Reish; Sherrie Davis; Jennifer L Cuzzocreo; Neil T Shepard; Dzung L Pham
Journal:  Exp Brain Res       Date:  2018-07-17       Impact factor: 1.972

9.  MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.

Authors:  Kerstin Bendfeldt; Bernd Taschler; Laura Gaetano; Philip Madoerin; Pascal Kuster; Nicole Mueller-Lenke; Michael Amann; Hugo Vrenken; Viktor Wottschel; Frederik Barkhof; Stefan Borgwardt; Stefan Klöppel; Eva-Maria Wicklein; Ludwig Kappos; Gilles Edan; Mark S Freedman; Xavier Montalbán; Hans-Peter Hartung; Christoph Pohl; Rupert Sandbrink; Till Sprenger; Ernst-Wilhelm Radue; Jens Wuerfel; Thomas E Nichols
Journal:  Brain Imaging Behav       Date:  2019-10       Impact factor: 3.978

Review 10.  Specialized Pro-Resolving Lipid Mediators: Emerging Therapeutic Candidates for Multiple Sclerosis.

Authors:  Insha Zahoor; Shailendra Giri
Journal:  Clin Rev Allergy Immunol       Date:  2021-04       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.